|
1
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Terakawa N, Kanamori Y and Yoshida S: Loss
of PTEN expression followed by Akt phosphorylation is a poor
prognostic factor for patients with endometrial cancer. Endocr
Relat Cancer. 10:203–208. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kondo Y, Hollingsworth EF and Kondo S:
Molecular targeting for malignant gliomas (Review). Int J Oncol.
24:1101–1109. 2004.PubMed/NCBI
|
|
6
|
Koksal IT, Dirice E, Yasar D, Sanlioglu
AD, Ciftcioglu A, Gulkesen KH, Ozes NO, Baykara M, Luleci G and
Sanlioglu S: The assessment of PTEN tumor suppressor gene in
combination with Gleason scoring and serum PSA to evaluate
progression of prostate carcinoma. Urol Oncol. 22:307–312. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Im SA, Lee KE, Nam E, Kim DY, Lee JH, Han
HS, Seoh JY, Park HY, Cho MS, Han WS, et al: Potential prognostic
significance of p185(HER2) overexpression with loss of PTEN
expression in gastric carcinomas. Tumori. 91:513–521. 2005.
|
|
8
|
Tang JM, He QY, Guo RX and Chang XJ:
Phosphorylated Akt overexpression and loss of PTEN expression in
non-small cell lung cancer confers poor prognosis. Lung Cancer.
51:181–191. 2006. View Article : Google Scholar
|
|
9
|
Toft DJ and Cryns VL: Minireview:
Basal-like breast cancer: from molecular profiles to targeted
therapies. Mol Endocrinol. 25:199–211. 2011. View Article : Google Scholar :
|
|
10
|
Tachibana M, Shibakita M, Ohno S, Kinugasa
S, Yoshimura H, Ueda S, Fujii T, Rahman MA, Dhar DK and Nagasue N:
Expression and prognostic significance of PTEN product protein in
patients with esophageal squamous cell carcinoma. Cancer.
94:1955–1960. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li P, Mao WM, Zheng ZG, Dong ZM and Ling
ZQ: Down-regulation of PTEN expression modulated by dysregulated
miR-21 contributes to the progression of esophageal cancer. Dig Dis
Sci. 58:3483–3493. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun Z, Ji N, Bi M, Zhang Z, Liu X and Wang
Z: Negative expression of PTEN identifies high risk for
lymphatic-related metastasis in human esophageal squamous cell
carcinoma. Oncol Rep. 33:3024–3032. 2015.PubMed/NCBI
|
|
13
|
Zhao H, Yang J, Fan T, Li S and Ren X:
RhoE functions as a tumor suppressor in esophageal squamous cell
carcinoma and modulates the PTEN/PI3K/Akt signaling pathway. Tumour
Biol. 33:1363–1374. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ou Y, Ma L, Ma L, Huang Z, Zhou W, Zhao C,
Zhang B, Song Y, Yu C and Zhan Q: Overexpression of cyclin B1
antagonizes chemotherapeutic-induced apoptosis through PTEN/Akt
pathway in human esophageal squamous cell carcinoma cells. Cancer
Biol Ther. 14:45–55. 2013. View Article : Google Scholar :
|
|
15
|
Sun MM, Zhang MZ, Chen Y, Li SL, Zhang W,
Ya GW and Chen KS: Effect of PTEN antisense oligonucleotide on
oesophageal squamous cell carcinoma cell lines. J Int Med Res.
40:2098–2108. 2012. View Article : Google Scholar
|
|
16
|
Zhou YA, Zhang T, Zhao JB, Wang XP, Jiang
T, Gu ZP, Wang XN and Li XF: The adenovirus-mediated transfer of
PTEN inhibits the growth of esophageal cancer cells in vitro and in
vivo. Biosci Biotechnol Biochem. 74:736–740. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wills KN, Atencio IA, Avanzini JB,
Neuteboom S, Phelan A, Philopena J, Sutjipto S, Vaillancourt MT,
Wen SF, Ralston RO, et al: Intratumoral spread and increased
efficacy of a p53-VP22 fusion protein expressed by a recombinant
adenovirus. J Virol. 75:8733–8741. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zavaglia D, Favrot MC, Eymin B, Tenaud C
and Coll JL: Intercellular trafficking and enhanced in vivo
antitumour activity of a non-virally delivered P27-VP22 fusion
protein. Gene Ther. 10:314–325. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jin G, Zhou Y, Chai Q, Zhu G, Xu F and Liu
F: VP22 and cytosine deaminase fusion gene modified
tissue-engineered neural stem cells for glioma therapy. J Cancer
Res Clin Oncol. 139:475–483. 2013. View Article : Google Scholar
|
|
20
|
Nishikawa M, Otsuki T, Ota A, Guan X,
Takemoto S, Takahashi Y and Takakura Y: Induction of tumor-specific
immune response by gene transfer of Hsp70-cell-penetrating peptide
fusion protein to tumors in mice. Mol Ther. 18:421–428. 2010.
View Article : Google Scholar :
|
|
21
|
Yu X, Xu Z, Lei J, Li T and Wang Y: VP22
mediates intercellular trafficking and enhances the in vitro
antitumor activity of PTEN. Mol Med Rep. 12:1286–1290.
2015.PubMed/NCBI
|
|
22
|
Regberg J, Srimanee A and Langel U:
Applications of cell-penetrating peptides for tumor targeting and
future cancer therapies. Pharmaceuticals (Basel). 5:991–1007. 2012.
View Article : Google Scholar
|
|
23
|
Kueltzo LA, Normand N, O'Hare P and
Middaugh CR: Conformational lability of herpesvirus protein VP22. J
Biol Chem. 275:33213–33221. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Elliott G and O'Hare P: Intercellular
trafficking and protein delivery by a herpesvirus structural
protein. Cell. 88:223–233. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Persad S, Attwell S, Gray V, Delcommenne
M, Troussard A, Sanghera J and Dedhar S: Inhibition of
integrin-linked kinase (ILK) suppresses activation of protein
kinase B/Akt and induces cell cycle arrest and apoptosis of
PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA.
97:3207–3212. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li Z, Liu GX, Liu YL, Chen X, Huang XL and
Gan HT: Effect of adenovirus-mediated PTEN gene on ulcerative
colitis-associated colorectal cancer. Int J Colorectal Dis.
28:1107–1115. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Maehama T and Dixon JE: The tumor
suppressor, PTEN/MMAC1, dephosphorylates the lipid second
messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem.
273:13375–13378. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cully M, You H, Levine AJ and Mak TW:
Beyond PTEN mutations: The PI3K pathway as an integrator of
multiple inputs during tumorigenesis. Nat Rev Cancer. 6:184–192.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Leslie NR, Yang X, Downes CP and Weijer
CJ: PtdIns(3,4,5) P(3)-dependent and -independent roles for PTEN in
the control of cell migration. Curr Biol. 17:115–125. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schwock J, Dhani N and Hedley DW:
Targeting focal adhesion kinase signaling in tumor growth and
metastasis. Expert Opin Ther Targets. 14:77–94. 2010. View Article : Google Scholar
|
|
31
|
Sieg DJ, Hauck CR, Ilic D, Klingbeil CK,
Schaefer E, Damsky CH and Schlaepfer DD: FAK integrates
growth-factor and integrin signals to promote cell migration. Nat
Cell Biol. 2:249–256. 2000. View
Article : Google Scholar : PubMed/NCBI
|
